Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Palmitoylethanolamide Co-ultramicronized With Luteoline (Pea-lut) on Frontal Lobe Functions and GABAergic Transmission in Long Covid Patients. An 8-week Randomized Controlled Trial.

NCT05311852 is registered in ClinicalTrials.gov with Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy as lead sponsor.

NCT NCT05311852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05311852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Palmitoylethanolamide Co-ultramicronized With Luteoline (Pea-lut) on Frontal Lobe Functions and GABAergic Transmission in Long Covid Patients. An 8-week Randomized Controlled Trial.
Lead sponsor
Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy
Phase
Not applicable
Overall status
Completed
Start date
August 16, 2021
Completion date
March 15, 2022
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive deficit, covid-19, fatigue, neurophysiologic abnormality